OIPE JC53 NOV 0 3 2003 PATENT

1647

PATENT
Attorney Docket No. MERCK-2056

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Hartmann *et al.*		
SERIAL NO.:	09/708,506	GROUP NO.:	1647
FILING DATE:	November 9, 2000	EXAMINER:	DeBerry, Regina M.
TITLE:	ERYTHROPOIETIN FORMS WITH IMPROVED PROPERTIES		

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 31st day of October, 2003.


Malecia Allen

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

1. Transmittal Form (1 page);
2. Fee Transmittal Form (1 page);
3. Information Disclosure Statement (2 pages);
4. Form PTO-1449 (19 pages);
5. Copies of cited references A1-A66, B1-B95, and C1-C181;
6. A check in the amount of $180.00; and
7. A return receipt postcard.



TRANSMITTAL FORM

Application Serial Number	09/708,506
Filing Date	November 9, 2000
First Named Inventor	Hartmann
Group Art Unit	1647
Examiner Name	DeBerry, Regina M.
Attorney Docket No.	MERCK-2056
Patent No.	Not applicable
Issue Date	Not applicable

ENCLOSURES *(check all that apply)*

- ☒ Fee Transmittal Form
 - ☒ Check Attached
 - ☐ Copy of Fee Transmittal Form
- ☐ Amendment/Response
 - ☐ Preliminary
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
 - ☐ Letter to Official Draftsperson including Drawings [Total Sheets _____]
- ☐ Petition for Extension of Time
- ☒ Information Disclosure Statement
 - ☒ Form PTO-1449
 - ☒ Copies of IDS Citations (A1-A66, B1-B95, and C1-C181)
- ☐ Certified Copy of Priority Document(s)
- ☐ Sequence Listing submission
 - ☐ Paper Copy/CD
 - ☐ Computer Readable Copy
 - ☐ Statement verifying identity of above
- ☐ Copy of Notice to File Missing Parts of Application
- ☐ Formal Drawing(s)
- ☐ Request For Continued Examination (RCE) Transmittal
- ☐ Power of Attorney (Revocation of Prior Powers)
- ☐ Terminal Disclaimer
- ☐ Executed Declaration and Power of Attorney for Utility or Design Patent Application
- ☐ Small Entity Statement
- ☐ CD(s) for large table or computer program
- ☐ Amendment After Allowance
- ☐ Request for Certificate of Correction
 - ☐ Certificate of Correction (in duplicate)
- ☐ Notice of Appeal to Board of Patent Appeals and Interferences
- ☐ Appeal Brief (in triplicate)
- ☐ Status Inquiry
- ☒ Return Receipt Postcard
- ☒ Certificate of First Class Mail
- ☐ Certificate of Facsimile Transmission under 37 C.F.R. 1.8
- ☐ Additional Enclosure(s) *(please identify below)*

CORRESPONDENCE ADDRESS

Direct all correspondence to:

Patent Administrator
Testa, Hurwitz & Thibeault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

Date: October 31, 2003
Reg. No. 48,645
Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100

Brian Fairchild, Ph.D.
Agent for Applicants
Testa, Hurwitz & Thibeault, LLP
High Street Tower
125 High Street
Boston, MA 02110

FEE TRANSMITTAL
FY 2004

OIPE JC53 NOV 03 2003 PATENT & TRADEMARK OFFICE

	Complete if Known
Application Serial Number	09/708,506
Filing Date	November 9, 2000
First Named Inventor	Hartmann
Group Art Unit	1647
Examiner Name	DeBerry, Regina M.
Attorney Docket No.	MERCK-2056

METHOD OF PAYMENT

1. ☒ Payment Enclosed:
 ☒ Check ☐ Money Order ☐ Other

2. ☒ The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 20-0531.
 ☐ Required Fees (copy of this sheet enclosed).
 ☒ Additional fee required under 37 CFR 1.16 and 1.17.
 ☒ Overpayment Credit.

3. ☐ Applicant claims small entity status.

FEE CALCULATION

1. FILING FEE

Large Entity Fee ($)	Fee Description	Fee Paid
770	Utility filing fee	
340	Design filing fee	
160	Provisional filing fee	

	Number Filed	Number Extra	Rate	Amount
Total Claims		- 20 =	x $ 18.00 =	
Independent Claims		- 3 =	x $ 86.00 =	
☐ Multiple Dependent Claim(s), if any			$290.00 =	

TOTAL:
SMALL ENTITY DISCOUNT:
SUBTOTAL (1) ($) 0.00

2. AMENDMENT CLAIM FEES

	Claims Remaining After Amend.	Highest No. Previously Paid For	Present Extra	Rate	Fee Paid
Total	-	=		x $ 18.00 =	
Indep.	-	=		x $ 86.00 =	
☐ First Presentation of Multiple Dep. Claim				+ $290.00 =	

TOTAL: ($)
SMALL ENTITY DISCOUNT: ($)
SUBTOTAL (2) ($) 0.00

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee ($)	Small Entity Fee ($)	Fee Description	Fee Paid
130	65	Surcharge - late filing fee or oath	
50	25	Surcharge - late provisional filing fee or cover sheet	
130	130	Non-English specification	
2,520	2,520	Request for ex parte reexamination	
110	55	Extension for reply within first month	
420	210	Extension for reply within second month	
950	475	Extension for reply within third month	
1480	740	Extension for reply within fourth month	
2010	1005	Extension for reply within fifth month	
330	165	Notice of Appeal	
330	165	Filing a brief in support of an appeal	
290	145	Request for oral hearing	
130	130	Petitions to the Commissioner	
180	180	Submission of Information Disclosure Statement	180.00
770	385	Filing a submission after final rejection (37 CFR 1.129(a))	
770	385	For each additional invention to be examined (37 CFR 1.129(b))	
100	100	Certificate of Correction for applicant's error	
110	55	Submission of Terminal Disclaimer	
Other fee (Specify)			
Other fee (Specify)			

SUBTOTAL (3) ($) 180.00

SUBTOTAL (1)	0.00
SUBTOTAL (2)	0.00
SUBTOTAL (3)	180.00

TOTAL ($) 180.00

CORRESPONDENCE ADDRESS

Direct all correspondence to:
Patent Administrator
Testa, Hurwitz & Thibeault, LLP
High Street Tower-125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

Date: October 31, 2003
Reg. No.: 48,645
Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100

Brian Fairchild, Ph.D.
Agent for the Applicants
Testa, Hurwitz & Thibeault, LLP
High Street Tower-125 High Street
Boston, MA 02110

OIPE JC53
NOV 03 2003
PATENT & TRADEMARK OFFICE

PATENT
Attorney Docket No. MERCK-2056

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Hartmann *et al.*	CONF. NO.:	2626
SERIAL NO.:	09/708,506	GROUP NO.:	1647
FILING DATE:	November 9, 2000	EXAMINER:	DeBerry, Regina M.
TITLE:	Erythropoietin Forms with Improved Properties		

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or

☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and

☐ the requisite Statement is below, **OR**

☒ the requisite fee under 37 C.F.R. 1.17(p), namely **$180.00**, is included herein, or

11/04/2003 SSANDARA 00000048 09708506
180.00 OP
01 FC:1806

☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**

☐ the requisite Statement is below, **AND**

☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Applicants believe no additional fee is due for consideration of this submission. Nevertheless, if such a fee is required, please debit account 20-0531.

Respectfully submitted,

Date: October 31, 2003
Reg. No. 48,645

Brian Fairchild, Ph.D.
Agent for Applicants
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100

2674340-1

CIPE JC53 NOV 03 2003 PATENT & TRADEMARK OFFICE

FORM PTO - 1449	ATTORNEY DOCKET NO.: MERCK-2056
INFORMATION DISCLOSURE STATEMENT	APPLICANTS: Hartmann *et al.*
	SERIAL NO.: 09/708,506 CONF. NO.: 2626
	FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A1	07/348,237	5/5/89	Rosenblum et al.			
	A2	4,196,265	4/1/80	Koprowski et al.			
	A3	4,469,797	9/4/84	Albarella			
	A4	4,676,980	6/30/87	Segal et al.			
	A5	4,816,567	3/28/89	Cabilly et al.			
	A6	4,946,778	8/7/90	Ladner et al.			
	A7	5,019,368	5/28/91	Epstein et al.			
	A8	5,073,627	12/17/91	Curtis et al.			
	A9	5,114,711	5/19/92	Bell et al.			
	A10	5,116,964	5/26/92	Capon et al.			
	A11	5,199,942	4/6/93	Gillis			
	A12	5,225,538	7/6/93	Capon et al.			
	A13	5,225,539	7/6/93	Winter			
	A14	5,258,498	11/2/93	Huston et al..			
	A15	5,314,995	5/24/94	Fell, Jr. et al.			
	A16	5,349,053	9/20/94	Landolfi			
	A17	5,359,035	10/25/94	Habermann			
	A18	5,514,582	5/7/96	Capon et al.			
	A19	5,538,866	7/23/96	Israeli et al.			
	A20	5,541,087	7/30/96	Lo et al.			
	A21	5,543,297	8/6/96	Cromlish, et al.			
	A22	5,552,524	09/03/96	Basinski et al.			
	A23	5,585,089	12/17/96	Queen et al.			

EXAMINER	DATE CONSIDERED

OIPE JC53 NOV 03 2003 PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A24	5,609,846	3/11/97	Goldenberg			
	A25	5,624,821	4/29/97	Winter et al.			
	A26	5,639,725	6/17/97	O'Reilly et al.			
	A27	5,645,835	7/8/97	Fell, Jr. et al.			
	A28	5,650,150	7/22/97	Gillies			
	A29	5,650,492	7/22/97	Gately et al.			
	A30	5,667,776	9/16/97	Zimmerman et al.			
	A31	5,679,543	10/21/97	Lawlis			
	A32	5,691,309	11/25/97	Basinski et al.			
	A33	5,709,859	1/20/98	Aruffo et al.			
	A34	5,719,266	02/17/98	DiMarchi et al.			
	A35	5,723,125	3/3/98	Chang et al.			
	A36	5,726,044	3/10/98	Lo et al.			
	A37	5,728,552	3/17/98	Fujisawa et al.			
	A38	5,733,876	3/31/98	O'Reilly et al.			
	A39	5,756,461	05/26/98	Stephens			
	A40	5,759,551	6/2/98	Ladd et al.			
	A41	5,770,195	6/23/98	Hudziak et al.			
	A42	5,800,810	9/1/98	Doyle et al.			
	A43	5,807,715	9/15/98	Morrison et al.			
	A44	5,827,516	10/27/98	Urban et al.			
	A45	5,837,682	11/17/98	Folkman et al.			
	A46	5,843,423	12/1/98	Lyman et al.			
	A47	5,854,205	12/29/98	O'Reilly et al.			
	A48	5,858,347	1/12/99	Bauer et al.			
	A49	5,885,795	3/23/99	O'Reilly et al.			

EXAMINER	DATE CONSIDERED

OIPE JC53
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A50	5,886,178	3/23/99	Allen et al.			
	A51	5,888,772	3/30/99	Okasinski et al.			
	A52	5,908,626	6/1/99	Chang et al.			
	A53	5,922,685	7/13/99	Rakhmilevich et al.			
	A54	5,994,126	11/30/99	Steinman et al.			
	A55	6,080,409	6/27/00	Laus et al.			
	A56	6,086,875	7/11/00	Blumberg et al.			
	A57	6,100,387	8/8/00	Herrmann et al.			
	A58	6,169,070 B1	1/2/01	Chen et al.			
	A59	6,171,588 B1	1/9/01	Carron et al.			
	A60	6,277,375 B1	8/21/01	Ward			
	A61	6,348,192 B1	2/19/02	Chan et al.			
	A62	6,406,689 B1	6/18/02	Falkenberg et al.			
	A63	6,444,792 B1	9/3/02	Gray et al.			
	A64	5,856,298	1/5/99	Strickland			
	A65	5,688,679	11/18/97	Powell			
	A66	5,441,868	8/15/95	Lin			

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B1	0 158 198 A1	10/16/85	EP					Y
	B2	0 211 769 A2	2/25/87	EP					Y
	B3	0 256 714 A2	2/24/88	EP					Y
	B4	0 294 703 A2	12/14/88	EP					Y
	B5	0 308 936 B1	3/29/89	EP					Y
	B6	0 314 317 B1	5/3/89	EP					Y

EXAMINER	DATE CONSIDERED

OIPE JC53 NOV 0 3 2003 PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B7	0 318 554 B1	6/7/89	EP					Y
	B8	0 319 012 A2	6/7/89	EP					Y
	B9	0 326 120 B1	8/2/89	EP					Y
	B10	0 350 230 A2	1/10/90	EP					Y
	B11	0 375 562 B1	6/27/90	EP					Y
	B12	0 396 387 A2	11/7/90	EP					Y
	B13	0 439 095 A2	7/31/91	EP					Y
	B14	0 511 747 A1	11/4/92	EP					Y
	B15	0 601 043 B1	6/15/94	EP					Y
	B16	0 706 799 A2	4/17/96	EP					Y
	B17	0 790 309 A1	8/20/97	EP					Y
	B18	21725/88	3/23/89	AU					Y
	B19	93100115.3	7/14/93	CN					N
	B20	93100115.3	7/14/93	CN				Y	Y
	B21	37 12985 A1	11/3/88	DE					N
	B22	37 12985	11/2/88	DE				Y	Y
	B23	2 292 382 A	2/21/96	GB					Y
	B24	63-267278	11/4/88	JP					N
	B25	63-267278	11/4/88	JP				Y	Y
	B26	63-267296	11/4/88	JP					N
	B27	63-267296	11/4/88	JP				Y	Y
	B28	0 237 019 A2	9/16/87	EP				English counterpart of 63-267296 (B26)	Y
	B29	WO 86/01533	3/13/86	PCT					Y
	B30	WO 88/00052	1/14/88	PCT					Y

EXAMINER	DATE CONSIDERED

OIPE JC53
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B31	WO 88/09344	12/1/88	PCT					Y
	B32	WO 89/02922	4/6/89	PCT					Y
	B33	WO 89/09620	10/19/89	PCT				Abstract in English	N
	B34	WO 90/03801	4/19/90	PCT					Y
	B35	WO 91/00360	1/10/91	PCT					Y
	B36	WO 91/04329	04/04/91	PCT					Y
	B37	WO 91/08298	6/13/91	PCT					Y
	B38	WO 91/13166	9/5/91	PCT					Y
	B39	WO 91/14438	10/3/91	PCT					Y
	B40	WO 92/02240	2/20/92	PCT					Y
	B41	WO 92/08495	5/29/92	PCT					Y
	B42	WO 92/08801	5/29/92	PCT					Y
	B43	WO 92/16562	10/1/92	PCT					Y
	B44	WO 93/03157	2/18/93	PCT					Y
	B45	WO 93/10229	5/27/93	PCT					Y
	B46	WO 95/05468	2/23/95	PCT					Y
	B47	WO 95/21258	8/10/95	PCT					Y
	B48	WO 95/28427	10/26/95	PCT					Y
	B49	WO 95/31483	11/23/95	PCT					Y
	B50	WO 96/04388	02/15/96	PCT					Y
	B51	WO 96/05309	2/22/96	PCT					Y
	B52	WO 96/08570	3/21/96	PCT					Y
	B53	WO 96/18412	6/20/96	PCT					Y
	B54	WO 96/31526	10/10/96	PCT					Y

EXAMINER	DATE CONSIDERED

NOV 0 3 2003
PATENT & TRADEMARK OFFICE
JC53

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B55	WO 97/00317	1/3/97	PCT					Y
	B56	WO 97/00319	1/3/97	PCT					Y
	B57	WO 97/15666	5/1/97	PCT					Y
	B58	WO 97/20062	6/5/97	PCT					Y
	B59	WO 97/24137	7/10/97	PCT					Y
	B60	WO 97/24440	7/10/97	PCT					Y
	B61	WO 97/26335	7/24/97	PCT					Y
	B62	WO 97/30089	8/21/97	PCT					Y
	B63	WO 97/33617	9/18/97	PCT					Y
	B64	WO 97/33619	9/18/97	PCT					Y
	B65	WO 97/34631	9/25/97	PCT					Y
	B66	WO 97/43316	11/20/97	PCT					Y
	B67	WO 98/00127	1/8/98	PCT					Y
	B68	WO 98/06752	2/19/98	PCT					Y
	B69	WO 98/28427	7/2/98	PCT					Y
	B70	WO 98/30706	7/16/98	PCT					Y
	B71	WO 98/46257	10/22/98	PCT					Y
	B72	WO 98/59244	12/30/98	PCT					Y
	B73	WO 99/02709	01/21/99	PCT					Y
	B74	WO 99/03887	01/28/99	PCT					Y
	B75	WO 99/29732	6/17/99	PCT					Y
	B76	WO 99/43713	9/2/99	PCT					Y
	B77	WO 99/52562	10/21/99	PCT					Y
	B78	WO 99/53958	10/28/99	PCT					Y

EXAMINER	DATE CONSIDERED

NOV 0 3 2003
PATENT & TRADEMARK OFFICE
JC53

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B79	WO 99/60128	11/25/99	PCT					Y
	B80	WO 99/62944	12/09/99	PCT					Y
	B81	WO 00/11033	3/2/00	PCT					Y
	B82	WO 00/34317	06/15/00	PCT					Y
	B83	WO 00/40615	7/13/00	PCT					Y
	B84	WO 00/69913	11/23/00	PCT					Y
	B85	WO 00/78334 A1	12/28/00	PCT					Y
	B86	WO 01/07081 A1	2/1/01	PCT					Y
	B87	WO 01/10912 A1	2/15/01	PCT					Y
	B88	WO 03/015697 A2	2/27/03	PCT					Y
	B89	0 640 619 A1	3/1/95	EP					Y
	B90	0 668 353 A1	8/23/95	EP					Y
	B91	WO 94/24160	10/27/94	PCT					Y
	B92	WO 94/25055	11/10/94	PCT					Y
	B93	WO 99/66054	12/23/99	PCT					Y
	B94	WO 00/68376	11/16/00	PCT					Y
	B95	WO 00/24893	5/4/00	PCT					Y

EXAM. INIT.		OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
	C1	Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization," Journal of Protein Chemistry, 11:5:433-444.
	C2	Abstract XP-002116766, (1996), "Prostaglandins, their inhibitors and cancer," Prostaglandins, Leukotrienes and Essential Fatty Acids, 54:2:83-94.
	C3	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," Science, 263:235-237.

EXAMINER	DATE CONSIDERED

OIPE JC53 NOV 0 3 2003 PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C4	Arenberg et al. (1996), "Interferon-γ-inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. Exp. Med, 184:981-992.
	C5	Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," J. Experimental Medicine, 167:612-622
	C6	Bachelot et al., (March 1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo," Proceedings of the Annual Meeting of the American Association for Cancer Research, 39:271, Abstract #1856.
	C7	Barnett et al., (1994), "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," Biochimica et Biophysica Acta, 1209:130-139.
	C8	Baselga, et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin ™) Enhances the Antitumor activity of Paclitazel and Doxorubicin against HER3/*neu* Overexpressing Human Breast Cancer Xenografts," Cancer Research, 58:2825-2831.
	C9	Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," Clinical Cancer Research, 5:4259-4263.
	C10	Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," Mol. Immunol., 30:379-386.
	C11	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," Proc. Natl. Acad. Sci., 93:7826-7831.
	C12	Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," Proc. Natl. Acad. Sci. USA, 93:2702-2707.
	C13	Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," Ann. Rev. Biochem., 57:505-518.
	C14	Bissery et al., (1997), "The Taxoids," in Cancer Therapeutics: Experimental and Clinical Agents, Teicher, ed., 175-193.
	C15	Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," Cancer Research, 45:1214-1221.
	C16	Boehm et al., (1997), "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," Nature, 390:404-407.
	C17	Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," Biochemical and Biophysical Research Communications, 252:190-194.

EXAMINER	DATE CONSIDERED

OIPE
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C18	Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," Cell, 79:1157-1164.
	C19	Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," Archives of Biochemistry and Biophysics, 307:2:411-415.
	C20	Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," Journal of Cell Biology, 111:2129-2138.
	C21	Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," Journal of Experimental Medicine, 173:6:1483-1491.
	C22	Cao et al., (1996), "Kringle Domains of Human Angiostatin," The Journal of Biological Chemistry, 271:46:29461-29467.
	C23	Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," The Journal of Biological Chemistry, 272:36:22924-22928.
	C24	Capon et al., (1989), "Designing CD4 immunoadhesins for AIDS therapy," Nature, 337:525-531.
	C25	Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," The EMBO Journal, 5:7:1577-1587.
	C26	Chan et al., (1991), "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," J. Exp. Med., pp. 869-879.
	C27	Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," Seminars in Surgical Oncology, 5:385-390.
	C28	Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," Journal of Biological Chemistry, 271:23:13349-13355.
	C29	Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," Nature, 335:370-372.
	C30	Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," Nature, 339:394-397.
	C31	Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," Journal of Immunology, 159:1:351-358.
	C32	Cheon et al., (1994), "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," Proc. Natl. Acad. Sci. USA, 91: 989-993.

EXAMINER	DATE CONSIDERED

OIPE JC53 NOV 0 3 2003 PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C33	Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," Gynecol. Oncol., 49:291-298.
	C34	Cohen, S. L. et al., (1996), "Human leptin characterization," Nature, 382:589.
	C35	Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," Journal of Immunology, 159:3613-3621.
	C36	Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," Proc. Natl. Acad. Sci, 85:7709-7713.
	C37	Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," Cancer Research, 56:2531-2534.
	C38	D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," Proc. Natl. Acad. Sci. USA, 91:4082-4085.
	C39	D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," J. Exp. Med., 176:1387-1398.
	C40	Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," Proceedings of the National Academy of Sciences of USA, 95:10443-10448.
	C41	Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," J. Cell. Biochem, Supp, 161:156-166.
	C42	Eisenthal, (1990), "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," Cancer Immunol. Immunotherap. 31:342-348.
	C43	Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," The J. of Immunology, 146:7:2446-2452.
	C44	Fell et al., (1992), "Chimeric L6 antitumor antibody," The J. of Biol. Chem., 267:15552-15558.
	C45	Friedman, J. M. et al., (1998), "Leptin and the regulation of body weight in mammals," Nature, 395:763-770.
	C46	Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," Science, 226:1339-1342.
	C47	Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses," Annu. Rev. Immunol., 16:495-521.
	C48	Gillessen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," Eur. J. Immunol., 25:200-206.

EXAMINER	DATE CONSIDERED

OIPE
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C49	Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," Bio/Technology, 7:799-804.
	C50	Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," J. Immunol. Methods, 125:191-202.
	C51	Gillies et al., (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," Hum. Antibod. Hybridomas, 1:1:47-54.
	C52	Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," Proc. Natl. Acad. Science, 89:1428-1432.
	C53	Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," Bioconjugate Chem., 4:230-235.
	C54	Gillies et al., (1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma matastases," J. Immunology, 160:2:6195-6203.
	C55	Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," Cancer Research, 59:2159-2166.
	C56	Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," Journal of Immunology, 120:6:2027-2032.
	C57	Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," Pharm. Sciences, pp. 597-609.
	C58	Gren et al., (1983), "A New Type of Leukocytic Interferon," Dokl. Biochem., 269:91-95.
	C59	Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," Cancer Research, 59:3776-3782.
	C60	Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," Blood, 73:8:2081-2805.
	C61	Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," Cancer Immunol. Immunother., 45:146-148.
	C62	Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," Tibtech, 11:42-44.
	C63	Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcYRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," Immunotech., 1:95-105.
	C64	Harvill et al., (1996), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation," Journal of Immunology, 157:7:3165-3170.

EXAMINER	DATE CONSIDERED

OIPE JC53
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.		OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
	C65	Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," Vaccine, 11:6:629-636.
	C66	He et al., (1998), "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," J. Immunol., 1029-1035.
	C67	Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcϒRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," J. Clin. Invest., 97:2:331-338.
	C68	Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," J. Immunol., 158:4381-4388.
	C69	Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," Proc. Natl. Acad. Sci., 83:18: 7059-7063.
	C70	Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," Ann. Rev. Immunol., 3:31-58.
	C71	Herrmann et al., (1989), "Hematopoeitic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," Journal of Clinical Oncology, 7:2:159-167.
	C72	Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," EMBO Journal, 17:6:1656-1664.
	C73	Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," Proceedings of the American Association for Cancer Research, 42:683, Abstract No. 3675.
	C74	Holden et al., (2001), "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," Clinical Cancer Research, 7:2862-2869.
	C75	Hoogenboom et al., (1991), "Construction and expression of antibody-tumor necrosis factor fusion proteins," Molecular Immunology, 28:9:1027-1037.
	C76	Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," Biochim. and Biophys. Acta, 1096:4:345-354 (Abstract).
	C77	Hornick et al, (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," Clin. Cancer Res., 5:51-60.
	C78	Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake[1]," Cancer Research, 56:4998-5004.
	C79	Huck et al., (1986), "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cγ genes," Nucleic Acids Research, Vol. 14:4:1779-1789.

EXAMINER	DATE CONSIDERED

OIPE JC53 NOV 0 3 2003 PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C80	Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science, 246:1275-1281.
	C81	Ingber et al., (1990), "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," Nature, 348:555-557.
	C82	Jones et al., (1986), "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature, 321:6069:522-525.
	C83	Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," Journal of Biological Chemistry, 262:12:5723-5731.
	C84	Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," Proc. Natl. Acad. Sci., 83:4479-4483.
	C85	Junghans et al., (1996), "The protection receptor of IgG catabolism is the B2-micorgobulin-containing neonatal intestinal transport receptor," Proc. Natl. Acad. Sci., 93:11:5512-5516.
	C86	Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," Proc. Natl. Acad. Sci., 88:11120-11123.
	C87	Kappel et al., (1992), "Regulating gene expression in transgenic animals," Current Opinion in Biotechnology 3:548-553
	C88	Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFcλ Receptor Antibodies," Journal of Experimental Medicine, 160:6:1686-1701.
	C89	Kendra et al., (1999), "Pharmacokinetics and Stability of the ch 14.18-Interleukin-2 Fusion Protein in Mice," Cancer Immunol. Immunotherapy, 48:219-229.
	C90	Kim et al., (1997), "An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production," Journal Immunology, 158:9:4137-4144.
	C91	Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," Journal of Interferon and Cytokine Research, 19:77-84.
	C92	Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes," Proc. Natl. Acad. Sci., 81:7922-7926.
	C93	Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," Journal of Cell Biology, 152:6:1233-1246.
	C94	LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," Journal of Biological Chemistry, 268:31:23311-23317.

EXAMINER	DATE CONSIDERED

OIPE JC53
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C95	Lazar et al., (1988), "Transforming Growth Factor α Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," Molecular and Cellular Biology, 8:3:1247-1252.
	C96	LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," Cancer Research, 51:2694-2698.
	C97	Lieschke, et al., (1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," Nature Biotechnology, 15:1:35-40.
	C98	Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," Journal of Experimental Medicine, 174:3:561-569.
	C99	Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," Proc. Natl. Acad. Sci., 82:8648-8652.
	C100	Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," Science, 239:395-398.
	C101	Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," Blood, 92:10:3730-3736.
	C102	Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," Protein Engineering, 11:6:495-500.
	C103	Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," Pharmacol. Thera., 80:3:277-292.
	C104	Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," Blood, 91:5:1706-1715.
	C105	Lode et al., (1999), "Synergy between an antiangiogenic integrin α_v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," Proc. Natl. Acad. Sci., 96:1591-1596.
	C106	Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," Proc. Natl. Acad. Sci., 96:8591-8596.
	C107	Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," Immunological Investigations, 29:2:117-120.
	C108	Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," Blood, 84:8:2457-2466.
	C109	Mark et al., (1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins," Journal of Biological Chemistry, 267:36:26166-26171.
	C110	Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," Eur. J. Immunol. 25:137-146.

EXAMINER	DATE CONSIDERED

NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C111	Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1[1]," J. Immunology, 158:5:2211-2217.
	C112	Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," Cancer Research, 57:2890-2895.
	C113	Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," Ann. Rev. Immunol, 7:145-173.
	C114	Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," J. Mol. Biol., 247:979-994.
	C115	Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," Immunopharmacol. Immunotoxicol., 20:4:473-492.
	C116	Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein," Proc. Natl. Acad. Sci., 83:8258-8262.
	C117	Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," Immunotoxins, 123-140.
	C118	Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," Nucleic Acids Research, 13:17:6361-6373.
	C119	Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," Cancer Research, 55:5451-5458.
	C120	Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," Proc. Nat. Acad. Sci, 96:3137-3142.
	C121	Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," Nature, 312:604-608.
	C122	O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell, 79:315-328.
	C123	O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," Nature Medicine, 2:6:689-692.
	C124	O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell, 88:277-285.
	C125	Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins," Journal of Biological Chemistry, 264:26:15157-15160.
	C126	Paul et al., (1988), "Lymphotoxin," Ann. Rev. Immunol., 6:407-438.

EXAMINER	DATE CONSIDERED

OIPE JC99
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C127	Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," J. Exp. Medicine, 163:166-178.
	C128	Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," Journal of Immunology, 142:10:3662-3667.
	C129	Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," Cancer Research, 59:1036-1040.
	C130	Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," Proc. Nat'l Acad. Sci., 94:20:10889-10894.
	C131	Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," Current Topics in Microbiology and Immunology, 27-53.
	C132	Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," Melanoma Research, 7:2:S99-S106.
	C133	Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," The Lancet, 343:1177-1183.
	C134	Roessler et al., (1994), "Cooperative interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-binding affinity of the receptor subunits," Proc. Natl. Acad. Sci., 91:3344-3347.
	C135	Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," Immunology, Third Edition, 8.3-8.4.
	C136	Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," Immunology Today, 9:2:58-62.
	C137	Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," Structure, 2:3:159-173.
	C138	Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," Cancer Research, 46:4701-4705.
	C139	Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," The EMBO Journal, 17:15:4249-4256.
	C140	Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the α chain (p55) of the interleukin 2 receptor," Proc. Natl. Acad. Sci., 88:4636-4640.
	C141	Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," Proc. Natl. Acad. Sci., 84:6904-6908.
	C142	Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," Journal of Immunology, 148:11:3433-3340.

EXAMINER	DATE CONSIDERED

NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C143	Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," Proc. Natl. Acad. Sci., 85:13:4842-4846.
	C144	Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," Nature Biotechnology, 18:1197-1202.
	C145	Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," Journal of Immunology, 163:5020-5028.
	C146	Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-λ and is not blocked by human IgG," Journal of Immunology, 137:11:3378-3382.
	C147	Shiff et al., (1995), "Sulindac Sulfide, an Asprin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," Journal of Clinical Investigation, 96:491-503.
	C148	Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," Proc. Natl. Acad. Sci., 87:5322-5326.
	C149	Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," Cancer Research, 57:1329-1334.
	C150	Stevenson et al., (1997), "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab'γ and Analogous Ligands," Journal of Immunology, 158:2242-2250.
	C151	Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," Adv. Cancer Research, 60:247-267.
	C152	Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," Nature, 302:305-309.
	C153	Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," Journal of Immunology, 143:8:2595-2601.
	C154	Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," Journal of Experimental Medicine, 178:2:661-667.
	C155	Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," Int. J. Cancer, 57:920-925.
	C156	The Merck Manual of Diagnosis and Therapy, 990-993, 1278-1283 (17th ed. 1999).
	C157	Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," Cancer Research, 48:5:1119-1123
	C158	Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," Science, 242:1166-1168

EXAMINER	DATE CONSIDERED

OIPE JC53
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.		OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
	C159	Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," Blood, 84:4008-4027.
	C160	Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," Cancer Research, 56:467-470.
	C161	Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," Cancer Research, 44:681-687.
	C162	Verhoeyen et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science, 239:1534-1536.
	C163	Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," Blood, 90:1:12-20.
	C164	Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," Blood, 90:9:3662-3672.
	C165	Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," Gene, 43:319-324.
	C166	Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," Protein Engineering, 1:6:493-498.
	C167	Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein on Type II Collagen-Induced Arthritis in Mice," Journal Immunology, 151: 6602-6607.
	C168	Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," Biochemical and Biophysical Research Communications, 236:651-654.
	C169	Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," Cancer Research, 57:4948-4955.
	C170	Zheng et al., (1995), "Administration of noncytolytic IL-10/Fc in muring models of lipopolysaccharide-induced septic shock and allogenic islet transplantation," Journal of Immunology, 154:5590-5600.
	C171	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," J. Biol. Chem., 269:3469-3474.
	C172	International Search Report for International Application No. PCT/EP00/10843, mailed July 20, 2001.
	C173	Boissel et al., (1993), "Erythropoietin Structure-Function Relationships," J. Biol. Chem., 268:15983-15993.
	C174	Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," Blood, 82:1507-1516.
	C175	Briggs et al., (1974), "Hepatic Clearance of Intact and Desialylated Erythropoietin," American Journal of Physiology, 227:1385-1388

EXAMINER	DATE CONSIDERED

OIPE
NOV 0 3 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann *et al.* SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C176	Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," Nephrol. Dial. Transplant., 16:3-13
	C177	Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," The Journal of Pharmacology and Experimental Therapeutics, 283:520-527
	C178	Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," Drug Metabolism and Disposition, 26:126-131
	C179	Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents – Pharmacokinetic and Pharmacodynamic Considerations," Nephrol. Dial. Transplant., 17:66-70
	C180	Nimtz et al., (1993), "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," Eur. J. Biochem., 213:39-56
	C181	Seidenfeld et al., (2001), "Epoetin Treatment of Anemia Associated with Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials," Journal of the National Cancer Institute, 93:1204-1214

EXAMINER	DATE CONSIDERED

2679871-1